Clinical trials: Mouth Neoplasms
Neoplasm, Cancer
Bioavailability and Food Effect Study of TKI258 (CSF Capsule vs. FMI Tablet) in Adult Patients With Advanced Solid Tumors
This study will evaluate the relative bioavailability of 2 oral formulations of TKI258, and the effect of food on the bioavailability of TKI258, in adult patients with advanced solid tumor.
- Conditions
- Neoplasm, Cancer, Tumors
- Trial name
- NCT01155713
- Testing
- TKI258
- Where
- 4 sites in United States
- Volunteers
- 63 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Myeloma, Diffuse Large B-Cell Lymphoma
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
The main purpose of this first human study with CC-223 is to assess the safety and action of a new class of experimental drug (dual mTOR inhibitors) in patients with advanced tumors unresponsive to standard therapies and to…
- Conditions
- Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma
- Trial name
- NCT01177397
- Testing
- CC-223
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 226 people
- Sponsor
- Celgene
Myeloid Leukemia, Chronic, Myeloid Leukemia, Chronic, Accelerated-Phase
Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)
This will be an open label, multi-center study of up to 77 patients with CML in chronic, accelerated or blast phase who have developed resistance to or have failed previous treatment with Gleevec (imatinib mesylate).
- Conditions
- Myeloid Leukemia, Chronic, Myeloid Leukemia, Chronic, Accelerated-Phase, Blast Phase, Myeloid Leukemia, Chronic, Chronic-Phase
- Trial name
- NCT00114959
- Testing
- Homoharringtonine, Imatinib Mesylate
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- ChemGenex Pharmaceuticals
Carcinoma, Non-Small-Cell Lung
LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer
The present trial will be performed to evaluate whether BIBF 1120 in combination with standard therapy of docetaxel in patients with stage IIIB/IV or recurrent NSCLC is more effective as compared to placebo in combination with…
- Trial name
- NCT00805194
- Testing
- BIBF 1120 plus docetaxel
- Where
- 210 sites in Austria, Belarus and 25 more
- Volunteers
- 1,314 people
- Sponsor
- Boehringer Ingelheim
Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men
Comparison of the Extent to Which the Drug Given as Two Different Capsule Sizes Becomes Available to the Body
Researchers are looking for a new way to treat women who have symptoms by hormonal changes, like those that happen in women during menopause. These symptoms can include hot flashes, night sweats, and changes in blood pressure.
- Trial name
- NCT04845841
- Testing
- Elinzanetant (BAY3427080) treatment A, Elinzanetant (BAY3427080) treatment B
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Bayer
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed or Refractory Pediatric Leukemia
This is a phase I/II pediatric dose-ranging study that will evaluate the safety, tolerability, clinical response, pharmacokinetics and pharmacodynamics of midostaurin in patients <18 years of age who have relapsed or refractory…
- Trial name
- NCT00866281
- Testing
- midostaurin
- Where
- 8 sites in United States, France and 3 more
- Volunteers
- 22 people
- Sponsor
- Novartis Pharmaceuticals
MPN (Myeloproliferative Neoplasms)
An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis
This is a study of itacitinib (INCB039110) in patients with myelofibrosis. This study will evaluate safety and efficacy parameters of itacitinib (INCB039110).
- Trial name
- NCT01633372
- Testing
- itacitinib
- Where
- 22 sites in United States, Australia and 1 more
- Volunteers
- 87 people
- Sponsor
- Incyte Corporation
Breast Cancer, Tumors
Study Evaluating Ascending Single-Dose Of Bosutinib Administered With Multiple Doses Of Ketoconazole To Healthy Subjects
The purpose of this study is to assess the safety and tolerability of ascending single oral doses of bosutinib administered with multiple doses of ketoconazole and to provide the pharmacokinetic profile of bosutinib when…
- Conditions
- Breast Cancer, Tumors, Leukemia
- Trial name
- NCT00777530
- Testing
- Bosutinib (SKI-606)
- Where
- Netherlands
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Mucositis, Nephrotoxicity
Treatment of Radiation and Cisplatin Induced Toxicities with Tempol
A 10 week trial to assess the ability of Tempol to prevent and/or reduce toxicities associated with cisplatin and radiation treatment in head and neck cancer patients.
- Conditions
- Mucositis, Nephrotoxicity, Ototoxicity
- Trial name
- NCT03480971
- Testing
- Tempol
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Matrix Biomed, Inc.
Tumor With Alterations of the FGF-R
A Phase I Study of Oral BGJ398 in Asian Patients
This study will evaluate safety and tolerability to determine the Maximum tolerated dose (MTD) and/or Recommended dose (RD).
- Trial name
- NCT01697605
- Testing
- BGJ398
- Where
- 8 sites in China, Japan
- Volunteers
- 9 people
- Sponsor
- Novartis Pharmaceuticals
Focal Cortical Dysplasia, Tuberous Sclerosis Complex (TSC)
Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Tuberous Sclerosis Complex (TSC) or Hemimegalencephaly (HME)
This is a multinational, open-label, single-arm trial of adjunctive SVG103 (paxalisib) treatment in adults with FCD-II, TSC, and HME.
- Conditions
- Focal Cortical Dysplasia, Tuberous Sclerosis Complex (TSC), Hemimegalencephaly
- Trial name
- NCT07287202
- Testing
- SVG103
- Where
- 2 sites in Australia
- Volunteers
- 12 people
- Sponsor
- Sovargen
Non-small Cell Lung Cancer
TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy
The purpose of this study is to compare the anti-tumor efficacy of oral single-agent rociletinib, as measured by investigator assessment of the PFS, with that of single-agent cytotoxic chemotherapy in patients with EGFR-mutated…
- Trial name
- NCT02322281
- Testing
- Rociletinib, Pemetrexed or gemcitabine or paclitaxel or docetaxel
- Where
- 80 sites in United States, Australia and 8 more
- Volunteers
- 149 people
- Sponsor
- Clovis Oncology, Inc.
Solid Tumors
Phase I Study of Indibulin in Patients With Solid Tumors
Dose-finding and pharmacokinetic trial of orally administered Indibulin to patients with solid tumors.
- Trial name
- NCT00591136
- Testing
- indibulin
- Where
- 2 sites in Netherlands
- Volunteers
- 47 people
- Sponsor
- Alaunos Therapeutics
Metastatic Breast Cancer
BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer
This is a prospective, multi-center, open-label, single arm, phase II study with a 2-stage design and Bayesian interim monitoring to investigate the safety and efficacy of BEZ235 in patients with progressive metastatic HR+ HER2…
- Trial name
- NCT01288092
- Testing
- BEZ235
- Sponsor
- Novartis Pharmaceuticals
Pain
Comparison of Nasal Fentanyl and Oral Transmucosal Fentanyl (Actiq) in Cancer Breakthrough Pain (FT-019-IM)
Primary: To compare the efficacy of nasal fentanyl (NF) to oral transmucosal fentanyl (Actiq®) (hereafter Actiq) in the management of breakthrough pain in cancer patients.
- Trial name
- NCT00496392
- Testing
- Nasal fentanyl
- Where
- Denmark
- Volunteers
- 115 people
- Sponsor
- Nycomed
Leiomyoma
Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1002670 (Vilaprisan)
Evaluate the potential effect of hepatic impairment on the pharmacokinetics, safety and tolerability of BAY1002670 (vilaprisan)
- Trial name
- NCT03092999
- Testing
- Vilaprisan (BAY1002670)
- Where
- 2 sites in Germany
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Bayer
Cutaneous T Cell Lymphoma, Mycosis Fungoides
A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat
Resminostat is a potent, orally available inhibitor of Class I, IIb and IV histone deacetylases (HDACs), including a pronounced activity against HDAC6.
- Conditions
- Cutaneous T Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome
- Trial name
- NCT04955340
- Testing
- [14C]-resminostat
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- 4SC AG
Neoplasms
Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid Tumours
A phase II trial to assess the impact of afatinib (BIBW 2992) on the heart (QTcF) and the effectiveness of afatinib (BIBW 2992) in treating certain cancers.
- Trial name
- NCT00875433
- Testing
- BIBW 2992
- Where
- 4 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- Boehringer Ingelheim
Oncology, Taste, Altered
Assessment of ONS-flavour Preference in Cancer Patients With and Without Taste Alterations
A single arm intervention study examining ONS-flavour preference in cancer patients with and without taste alterations
- Trial name
- PREFER (NCT05518825)
- Testing
- Fortimel/Nutridrink Compact Protein
- Where
- Netherlands
- Volunteers
- 64 people
- Sponsor
- Nutricia Research
Solid Tumour
Study of PHA-848125AC in Adult Patients With Advanced/Metastatic Solid Tumors
The purpose of this open-label, multi center, Phase I study was to determine the safety profile of the oral compound PHA-848125AC administered according to two different schedules of administrations to advanced/metastatic solid…
- Trial name
- NCT01300468
- Testing
- PHA-848125AC
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Nerviano Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.